 Merck  Co said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of  in a midstage trial supporting advancement of the study The drug maker said it has initiated a Phase  trial after analyzing the study results of the week regimen using the oral treatment which combines MK and MK The company said the study also showed a  cure rate for patients receiving those treatments plus ribavirin